Progenity Signs an Agreement with Ionis Pharmaceuticals to Evaluate Oral Biotherapeutics Delivery System with Antisense Oligonucleotides

 Progenity Signs an Agreement with Ionis Pharmaceuticals to Evaluate Oral Biotherapeutics Delivery System with Antisense Oligonucleotides

Progenity Signs an Agreement with Ionis Pharmaceuticals to Evaluate Oral Biotherapeutics Delivery System with Antisense Oligonucleotides

Shots:

  • In the P-I study, the companies will evaluate the OBDS with Ionis’ drug for in vitro compatibility and performance as well as in vivo safety, tolerability, and performance in a preclinical canine model
  • Progenity expects that the alliance could demonstrate the versatility of OBDS in delivering a range of different molecules
  • Ionis’ novel antisense therapies are designed to target mRNA, either decrease disease-causing proteins or increase the production of a needed protein while Progenity’s OBDS is an ingestible capsule based on a needle-free technology to enable the delivery of a drug formulated in a solution directly into the tissues of the small intestine

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: BusinessWire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post